Institute Group Leaders awarded promotions in the University
We are delighted to announce that two of our Senior Group Leaders, Jason Carroll and Masashi Narita, have been promoted to professors in this years’ round of Senior Academic Promotions.

Both have been assigned to the Department of Oncology, where their professorships will take effect from 1 October 2019. They join 41 other world-leading researchers who have been promoted to professors across the University of Cambridge.
Jason Carroll has been promoted to Professor of Molecular Oncology. Carroll’s research at the Institute focuses on the oestrogen receptor, which switches on genes in breast cancer cells causing the cells to grow. By understanding how the oestrogen receptor switches genes on and how drugs like tamoxifen work to switch them off, the team hope to learn more about how cancers develop resistance to these drugs. This information can help to make better and more effective drugs for cancer treatments.
Masashi Narita has been promoted to the position of Professor of Senobiology. Narita’s team are studying how to permanently stop the growth of tumour cells. In response to internal and external stresses, cells can choose to either die or to stop cell division permanently in order to remove unhealthy cells. Permanently stopping cell growth causes many changes in cells, affecting gene expression and how proteins are processed within the cell. By understanding the mechanisms of these changes, the Narita Group are working to provide new and alternative tools to tackle cancers.
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more